AUSTIN, Texas, Feb. 24, 2015 /PRNewswire/ -- XBiotech announced today that it plans to conduct an initial public offering of its common stock. The offering is expected to commence after the SEC completes the review process of its registration statement, which it publicly filed with the SEC on February 2, 2015, subject to market and other conditions. The number of shares to be offered and the price range for the offering have not yet been determined.
This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
ABOUT XBIOTECH
XBiotech is a leading developer of next generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development.
Contact:
Ashley Otero
XBiotech
aotero@xbiotech.com
512.386.2930
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xbiotech-plans-to-conduct-initial-public-offering-of-its-common-stock-300040491.html
SOURCE XBiotech
Help employers find you! Check out all the jobs and post your resume.
